Payment overview · 2025
General Payments
$689.79
28 reported records · 10 companies
Healthcare provider profile · identity verified
Gregory E Dodson, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · THOMASVILLE, GA · NPI 1699706911
Verified facts
What the public records show
CMS Open Payments records show Gregory E Dodson, PAC received $689.79 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $250.45 | 36.3% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.14 | 29.4% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $63.15 | 9.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.68 | 4.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.26 | 4.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.25 | 4.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.87 | 3.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.06 | 2.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.81 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.12 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $689.79 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $228.26 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $187.38 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.27 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $63.15 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.25 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.87 | 3 | 2025 |
Source payment records
|
|||||
| Vesicare Normalized: vesicare |
Drug | Astellas Pharma US Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 768 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 685 | 143 |
| Tramadol Hcl | Tramadol Hcl | 555 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 412 | 89 |
| Potassium Chloride | Potassium Chloride | 343 | 61 |
| Metformin Hcl | Metformin Hcl | 338 | 79 |
| Lisinopril | Lisinopril | 317 | 70 |
| Gabapentin | Gabapentin | 289 | 50 |
| Omeprazole | Omeprazole | 244 | 44 |
| Famotidine | Famotidine | 212 | 41 |
| Furosemide | Furosemide | 197 | 37 |
| Lovastatin | Lovastatin | 181 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 172 | 34 |
| Trazodone Hcl | Trazodone Hcl | 164 | 25 |
| Meloxicam | Meloxicam | 158 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 29 |
| Losartan Potassium | Losartan Potassium | 135 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 26 |
| Carvedilol | Carvedilol | 121 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 28 |
| Terazosin Hcl | Terazosin Hcl | 115 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 109 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 22 |
| Allopurinol | Allopurinol | 102 | 22 |
| Farxiga | Dapagliflozin Propanediol | 101 | 27 |
| Glipizide | Glipizide | 94 | 20 |
| Atenolol | Atenolol | 92 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | suppressed |
| Ozempic | Semaglutide | 83 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 15 |
| Montelukast Sodium | Montelukast Sodium | 75 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 12 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Glimepiride | Glimepiride | 59 | suppressed |
| Simvastatin | Simvastatin | 58 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 15 |
| Eliquis | Apixaban | 56 | 13 |
| Nifedipine Er | Nifedipine | 55 | 13 |
| Spironolactone | Spironolactone | 54 | 11 |
| Prednisone | Prednisone | 52 | 15 |
| Lorazepam | Lorazepam | 49 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 13 |
| Linzess | Linaclotide | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | 11 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 22 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Cequa | Cyclosporine | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lupron Depot | Leuprolide Acetate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $689.79 · 28 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, Vesicare, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error